Journal: Human Vaccines & Immunotherapeutics

Article Title: Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy

doi: 10.4161/hv.27217

Figure Lengend Snippet: Figure 1. ( A ) Clinical course from the beginning of the GPC3 peptide vaccination. Serum levels of CA125 and CA72–4 decreased after the initiation of therapy. Black arrows indicate vaccinations. The asterisk indicates right inguinal lymph node resection biopsy. The double asterisk indicates bilateral inguinal lymphadenectomy. ( B ) Contrast-enhanced CT scan showing liver (white, red, blue, and orange arrows) and paraaortic lymph node (yellow arrows) metastases. The size of metastases increased immediately following the initiation of the GPC3 peptide vaccination; however, tumor sizes decreased markedly within three months. ( C, D ) Pathological findings of primary ovarian carcinoma ( C ) and right inguinal lymph node biopsy specimens ( D ). A microscopy image of a hematoxylin and eosin (H&E)-stained section shows CCC ( a, i ). Immunohistochemical staining for GPC3 and HLA class I showed positivity in the primary ovarian carcinoma, respectively ( b, c ). Most CCC cells in the resected right inguinal lymph node metastasis appeared to lack GPC3 expression and a reduction in the expression of HLA class I ( ii, iii ). Immunohistochemical analysis showed a few CD8-positive T cells in the primary ovarian CCC tissue ( d ), whereas there was little infiltration of CD8-positive T cells in the resected right inguinal lymph node metastasis ( iv ). Original magnification, x200.

Article Snippet: The serum-soluble protein GPC3 was detected by indirect ELISA using an anti-human GPC3 monoclonal antibody (clone 1G12), anti-human GPC3 sheep polyclonal antibody (R&D Systems), and recombinant human GPC3 (R&D Systems).

Techniques: Computed Tomography, Microscopy, Staining, Immunohistochemical staining, Expressing

Journal: Human Vaccines & Immunotherapeutics

Article Title: Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy

doi: 10.4161/hv.27217

Figure Lengend Snippet: Figure 2. ( A ) Clinical course from the beginning of the GPC3 peptide vaccination. Serum levels of CA19–9 and CA125 decreased after the 7th vaccination. The CA19–9 level decreased to within the normal range. Black arrows indicate vaccinations. ( B ) Plain CT and 18 F-FDG PET/CT scans showing retroperitoneal lymph node (white, red, blue and orange arrows) and Virchow's node (yellow arrows) metastases. These metastases were negative on 18 F-FDG PET/CT at week 49. ( C ) Pathological findings of primary ovarian carcinoma. A microscopy image of a hematoxylin and eosin (H&E)-stained section shows CCC ( a ). Immunohistochemical staining was performed for GPC3, HLA class I, and CD8. ( b, c, d ). The expression of HLA class I was positive, while that of GPC3 was not, and there was no infiltration of CD8-positive T cells. Original magnification, x200.

Article Snippet: The serum-soluble protein GPC3 was detected by indirect ELISA using an anti-human GPC3 monoclonal antibody (clone 1G12), anti-human GPC3 sheep polyclonal antibody (R&D Systems), and recombinant human GPC3 (R&D Systems).

Techniques: Positron Emission Tomography-Computed Tomography, Microscopy, Staining, Immunohistochemical staining, Expressing

Journal: Molecular Therapy

Article Title: A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma

doi: 10.1016/j.ymthe.2017.08.005

Figure Lengend Snippet: Antitumor Effect of LC/GPC3+ in C57/B6 Mice

Article Snippet: GPC3 protein (5 μg/mL) and peptides GPC3 395–404 KSFINFYSAL (H2-K b restricted) and GPC3 418–427 DTLCWNGQEL (H2-D b restricted) (10 μg/mL, synthesized by GenScript, Piscataway, NJ) were used as stimulators.

Techniques:

Journal: Molecular Therapy

Article Title: A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma

doi: 10.1016/j.ymthe.2017.08.005

Figure Lengend Snippet: GPC3-Specific Antitumor Effect in the BALB/c HCC Model

Article Snippet: GPC3 protein (5 μg/mL) and peptides GPC3 395–404 KSFINFYSAL (H2-K b restricted) and GPC3 418–427 DTLCWNGQEL (H2-D b restricted) (10 μg/mL, synthesized by GenScript, Piscataway, NJ) were used as stimulators.

Techniques: